Y0000501
群多普利
European Pharmacopoeia (EP) Reference Standard
别名:
(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, Mavik
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C24H34N2O5
CAS号:
分子量:
430.54
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
API 家族
trandolapril
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O
InChI
1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
InChI 密鑰
VXFJYXUZANRPDJ-WTNASJBWSA-N
基因資訊
human ... ACE(1636)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Trandolapril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Danger
危險聲明
危險分類
Repr. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
M Buksa
Medicinski arhiv, 54(2), 103-106 (2000-08-10)
Left ventricle systolic dysfunction and congestive heart failure after AMI are still a great problem in cardiology. Introduction of angiotensin converting enzyme (ACE) inhibitors after AMI has been a new step in therapy of the left ventricle systolic disfunction. Some
C A Gaillard et al.
American heart journal, 125(5 Pt 2), 1542-1546 (1993-05-01)
In this article the clinical experiences with the new non-sulfhydryl angiotensin-converting enzyme inhibitor trandolapril are reviewed. The drug lowers blood pressure effectively in patients with mild-to-severe hypertension including elderly and obese patients. Distinguishing features of the compound are its long
Ariel Diaz et al.
Vascular health and risk management, 4(6), 1147-1158 (2008-01-01)
Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine.
H Holzgreve
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 15(2), S51-S53 (1997-03-01)
ADVANTAGES OF DRUG COMBINATIONS: The particular advantage usually sought with antihypertensive drug combinations is an improvement in blood pressure control. However, at least as important is a consideration of adverse reactions and the safety of the combination compared to monotherapy.
Sanjib Kumar Sharma et al.
Vascular health and risk management, 3(4), 453-465 (2007-11-01)
Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门